Skip to main content

Alnylam Begins Clinical Trials of ATTR, Hypercholesterolemia Drugs


NEW YORK (GenomeWeb) – Alnylam Pharmaceuticals this week announced that it has initiated two new clinical trials, a Phase III study of its TTR-mediated amyloidosis (ATTR) drug revusiran and a Phase I study of its hypercholesterolemia therapy ALN-PCSsc.

Both drugs are administered subcutaneously using Alnylam's GalNAc conjugates.

ATTR is a condition characterized by the accumulation of amyloid deposits in tissues due to mutations in the TTR gene. Revusiran is designed to silence both mutant and wild-type TTR.

The Phase III trial will test revusiran in up to 200 ATTR patients with a manifestation of the disease called familial amyloidotic cardiomyopathy. Primary endpoints of the study are changes in a measurement of how far patients walk over a six-minute period and the reduction in TTR burden between treated and placebo-controlled patients after 18 months.

ALN-PCSsc is designed to silence proprotein convertase subtilisn/kexin type 9, or PCSK9, which has been shown to regulate low-density lipoprotein receptor levels and play a role in plasma low-density lipoprotein clearance.

The study will test single ascending and multiple doses of ALN-PCSsc in up to 76 healthy volunteers.

ALN-PCSsc is being developed in collaboration with The Medicines Company. Initiation of the trial triggered a $10 million milestone payment to Alnylam.

The Scan

And For Adolescents

The US Food and Drug Administration has authorized the Pfizer-BioNTech SARS-CoV-2 vaccine for children between the ages of 12 and 15 years old.

Also of Concern to WHO

The Wall Street Journal reports that the World Health Organization has classified the SARS-CoV-2 variant B.1.617 as a "variant of concern."

Test for Them All

The New York Times reports on the development of combined tests for SARS-CoV-2 and other viruses like influenza.

PNAS Papers on Oral Microbiome Evolution, Snake Toxins, Transcription Factor Binding

In PNAS this week: evolution of oral microbiomes among hominids, comparative genomic analysis of snake toxins, and more.